Barclays raised the firm’s price target on West Pharmaceutical (WST) to $310 from $275 and keeps an Equal Weight rating on the shares. The firm updated the company’s model following the Q1 upside.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- The Week That Was, The Week Ahead: Macro and Markets, April 26
- West Pharmaceutical price target raised to $400 from $375 at Citi
- West Pharmaceutical price target raised to $390 from $320 at Evercore ISI
- West Pharmaceutical Lifts Outlook After Powerful Q1
- Early notable gainers among liquid option names on April 23rd